DK1155692T3 - Anvendelse af med albumin stabiliseret paclitaxel til fremstilling af et lægemiddel til behandling af faste tumorer, samt det således opnåede lægemiddel - Google Patents

Anvendelse af med albumin stabiliseret paclitaxel til fremstilling af et lægemiddel til behandling af faste tumorer, samt det således opnåede lægemiddel

Info

Publication number
DK1155692T3
DK1155692T3 DK01110509T DK01110509T DK1155692T3 DK 1155692 T3 DK1155692 T3 DK 1155692T3 DK 01110509 T DK01110509 T DK 01110509T DK 01110509 T DK01110509 T DK 01110509T DK 1155692 T3 DK1155692 T3 DK 1155692T3
Authority
DK
Denmark
Prior art keywords
drug
treatment
solid tumors
manufacture
well
Prior art date
Application number
DK01110509T
Other languages
Danish (da)
English (en)
Inventor
Marco Falciani
Original Assignee
Acs Dobfar Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11445079&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1155692(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acs Dobfar Spa filed Critical Acs Dobfar Spa
Application granted granted Critical
Publication of DK1155692T3 publication Critical patent/DK1155692T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5169Proteins, e.g. albumin, gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5052Proteins, e.g. albumin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK01110509T 2000-05-18 2001-04-27 Anvendelse af med albumin stabiliseret paclitaxel til fremstilling af et lægemiddel til behandling af faste tumorer, samt det således opnåede lægemiddel DK1155692T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2000MI001107A ITMI20001107A1 (it) 2000-05-18 2000-05-18 Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel

Publications (1)

Publication Number Publication Date
DK1155692T3 true DK1155692T3 (da) 2004-08-09

Family

ID=11445079

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01110509T DK1155692T3 (da) 2000-05-18 2001-04-27 Anvendelse af med albumin stabiliseret paclitaxel til fremstilling af et lægemiddel til behandling af faste tumorer, samt det således opnåede lægemiddel

Country Status (23)

Country Link
US (1) US6652884B2 (es)
EP (1) EP1155692B1 (es)
JP (1) JP2001354559A (es)
KR (2) KR20010105248A (es)
CN (1) CN1198609C (es)
AT (1) ATE267594T1 (es)
AU (1) AU781517B2 (es)
BR (1) BR0102040A (es)
CA (1) CA2345482A1 (es)
DE (1) DE60103453T2 (es)
DK (1) DK1155692T3 (es)
ES (1) ES2221874T3 (es)
HK (1) HK1040368A1 (es)
HU (1) HU229909B1 (es)
IL (1) IL142674A0 (es)
IT (1) ITMI20001107A1 (es)
MX (1) MXPA01004980A (es)
NO (1) NO330511B1 (es)
NZ (1) NZ511201A (es)
PT (1) PT1155692E (es)
RU (1) RU2270003C2 (es)
TR (1) TR200101353A2 (es)
ZA (1) ZA200103755B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070092563A1 (en) * 1996-10-01 2007-04-26 Abraxis Bioscience, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
HUP9701554D0 (en) * 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
ITMI20020680A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
ITMI20020681A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
AU2003299590B8 (en) 2002-12-09 2010-04-08 Abraxis Bioscience, Llc Compositions and methods of delivery of pharmacological agents
US7670627B2 (en) * 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
CN1925874B (zh) * 2002-12-09 2014-12-17 阿布拉西斯生物科学有限责任公司 组合物和传递药剂的方法
US20040224019A1 (en) * 2004-03-03 2004-11-11 Adi Shefer Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs
AU2006249235B2 (en) 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
PL3248600T3 (pl) * 2005-02-18 2020-09-07 Abraxis Bioscience, Llc Połączenia i sposoby podawania środków terapeutycznych i terapia skojarzona
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
BRPI0615265A8 (pt) 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
JP5368093B2 (ja) 2005-08-31 2013-12-18 アブラクシス バイオサイエンス, エルエルシー 増大した安定性を有する難水溶性薬剤の組成物および調製の方法
CA2626016A1 (en) * 2005-10-21 2007-06-21 Panacea Biotec Limited Pharmaceutical composition comprising at least one anticancer drug and at least one polymer
US20080280987A1 (en) * 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
ES2700074T3 (es) 2006-12-14 2019-02-13 Abraxis Bioscience Llc Terapia para el cáncer de mama sobre la base del estado de los receptores hormonales con nanopartículas que comprenden taxano
PL2481402T3 (pl) 2007-03-07 2018-11-30 Abraxis Bioscience, Llc Nanocząstka zawierająca rapamycynę i albuminę jako środek przeciwnowotworowy
WO2008137148A2 (en) * 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Methods and compositions for treating pulmonary hypertension
JP5579057B2 (ja) 2007-06-01 2014-08-27 アブラクシス バイオサイエンス, エルエルシー 再発性癌の処置のための方法および組成物
WO2009126401A1 (en) * 2008-04-10 2009-10-15 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
KR101090505B1 (ko) * 2008-12-30 2011-12-06 최은아 난담반을 포함하는 암 예방 및 치료용 조성물
HUE047376T2 (hu) 2009-04-15 2020-04-28 Abraxis Bioscience Llc Prionmentes nanorészecske-készítmények és elõállításuk
LT2552438T (lt) 2010-03-26 2016-09-26 Abraxis Bioscience, Llc Hepatoceliulinės karcinomos gydymo būdai
KR20130028727A (ko) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
NZ628423A (en) 2010-03-29 2016-03-31 Abraxis Bioscience Llc Methods of treating cancer
SG186112A1 (en) 2010-06-04 2013-01-30 Abraxis Bioscience Llc Methods of treatment of pancreatic cancer
CN103648521A (zh) 2011-04-28 2014-03-19 阿布拉科斯生物科学有限公司 纳米颗粒组合物的血管内递送及其应用
RU2705998C2 (ru) 2011-12-14 2019-11-13 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Применение полимерных эксципиентов для лиофилизации или заморозки частиц
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
EP2968254B1 (en) 2013-03-12 2020-04-22 Abraxis BioScience, LLC Methods of treating lung cancer
WO2014143613A1 (en) * 2013-03-13 2014-09-18 Abraxis Bioscience, Llc Methods of treatment of pediatric solid tumor
KR20150127187A (ko) 2013-03-14 2015-11-16 아브락시스 바이오사이언스, 엘엘씨 방광암의 치료 방법
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
AU2016285720C1 (en) 2015-06-29 2022-02-03 Abraxis Bioscience, Llc Methods of treating epithelioid cell tumors
WO2018037595A1 (ja) * 2016-08-26 2018-03-01 哲治 奥野 微小血管血流低減剤およびその利用
TWI660728B (zh) 2018-02-09 2019-06-01 國立交通大學 胺基喹唑啉衍生物及其醫藥組合物與用途
SG11202009145PA (en) 2018-03-20 2020-10-29 Abraxis Bioscience Llc Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
MX2022004989A (es) 2019-10-28 2022-07-21 Abraxis Bioscience Llc Composiciones farmaceuticas de albumina y rapamicina.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9405798A (pt) 1993-02-22 1995-12-12 Vivorx Pharmaceuticals Inc Métodos para liberação in vivo de material biológico e composições úteis dos mesmos
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
HU230338B1 (hu) * 1997-06-27 2016-02-29 Abraxis Bioscience Llc Gyógyászati hatóanyagokat tartalmazó új készítmények, eljárás ilyen készítmények előállítására és alkalmazására
EP1100494A1 (en) 1998-07-30 2001-05-23 Novopharm Biotech, Inc. Pharmaceutically composition comprising an aqueous solution of paclitaxel and albumin

Also Published As

Publication number Publication date
BR0102040A (pt) 2002-03-19
IL142674A0 (en) 2002-03-10
CN1324613A (zh) 2001-12-05
HUP0102039A2 (hu) 2002-05-29
DE60103453T2 (de) 2005-06-23
KR20080091747A (ko) 2008-10-14
TR200101353A3 (tr) 2001-12-21
TR200101353A2 (tr) 2001-12-21
NO20012409D0 (no) 2001-05-16
US20010046961A1 (en) 2001-11-29
NZ511201A (en) 2002-11-26
PT1155692E (pt) 2004-09-30
AU781517B2 (en) 2005-05-26
CA2345482A1 (en) 2001-11-18
ZA200103755B (en) 2001-11-15
ES2221874T3 (es) 2005-01-16
HK1040368A1 (en) 2002-06-07
MXPA01004980A (es) 2002-08-06
HU229909B1 (en) 2014-12-29
NO20012409L (no) 2001-11-19
EP1155692B1 (en) 2004-05-26
AU3876501A (en) 2001-11-22
HUP0102039A3 (en) 2002-12-28
CN1198609C (zh) 2005-04-27
KR20010105248A (ko) 2001-11-28
HU0102039D0 (en) 2001-07-30
ITMI20001107A0 (it) 2000-05-18
ATE267594T1 (de) 2004-06-15
US6652884B2 (en) 2003-11-25
RU2270003C2 (ru) 2006-02-20
ITMI20001107A1 (it) 2001-11-18
EP1155692A1 (en) 2001-11-21
DE60103453D1 (de) 2004-07-01
NO330511B1 (no) 2011-05-09
JP2001354559A (ja) 2001-12-25

Similar Documents

Publication Publication Date Title
DK1155692T3 (da) Anvendelse af med albumin stabiliseret paclitaxel til fremstilling af et lægemiddel til behandling af faste tumorer, samt det således opnåede lægemiddel
DK1292594T3 (da) Quinazolinderivater til behandling af tumorer
CY2014008I2 (el) Παραγωγα κιναζολινης, φαρμακα που περιεχουν τις ενωσεις αυτες, χρηση αυτων και μεθοδους για την παραγωγη τους
IS7857A (is) Setnar pýrróló-pýrasól afleiður sem kínasa hindrar
CY1113312T1 (el) Κυκλικοι αναστολεις κινασης τυροσινης πρωτεϊνων
DK1066269T3 (da) Trisubstituerede 1,3,5-triazinderivater til behandling af HIV-infektioner
DK1439829T3 (da) Lægemiddel indeholdende 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol med forsinket frigivelse af det aktive stof
CY1108067T1 (el) Υποκατεστημενα παραγωγα 2-πυριδινο-κυκλοεξανο-1,4-διαμινης
NO20031018D0 (no) Oksymorfonpreparater med kontrollert frigivelse
DK1443955T3 (da) PDGF-BB til behandling af Parkinsons sygdom
DK1265889T3 (da) Lægemidler imod virussygdomme
DE69925133D1 (de) Pyrrolobenzodiazepine
DK1259512T3 (da) Pteridinforbindelser til behandling af psoreasis
DK1242060T3 (da) Behandling af metastatisk sygdom
HRP20080447T3 (en) 7-(2-(4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydro-pyrid-1-yl)ethyl) isoquinoline besylate salt, preparation and therapeutic use thereof
DK0979079T3 (da) Anvendelse af tetrahydropyridinderivater til fremstilling af lægemidler til behandling af sygdomme, der medförer en demyelinisering
AR028705A1 (es) Bis-arilsulfonas
DK1214061T3 (da) Anvendelse af docetaxel til behandling af hepatocellulært carcinom
DE60112960D1 (de) Kondensierte pyridoindolderivate
NO20014752D0 (no) Taksanpreparater med forbedret opplöselighet
EE05241B1 (et) Distamtsiini a-halogenoakrlolderivaadi kasutamine
DK1615668T3 (da) Et lægemiddel til to-trins perioperativ behandling af faste tumorer med radioimmunoterapi
IS2441B (is) Notkun á pýridóindólon afleiðum til framleiðslu lyfja gegn krabbameini
DK1436277T3 (da) Fremgangsmåde til fremstilling af 14beta-hydroxy-baccatin III-1,14-carbonat
IL182125A0 (en) Optically active 4,4-di-substituted oxazolidine derivatives and processes for the preparation thereof